New Obesity Drug Targeting Appetite Yields Ten Percent Weight Loss

Petrelintide Lowers Body Weight Through Amylin Signaling

A new obesity drug targeting appetite through the pancreatic hormone amylin enabled participants to lose more than 10 percent of their body weight in a randomized clinical trial. Investigators presented the Phase 2 findings at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy, with concurrent publication in The Lancet Diabetes & Endocrinology. Petrelintide is an investigational once-weekly subcutaneous injection designed to mimic amylin rather than targeting incretin pathways like existing therapies.

While petrelintide produced less total weight reduction than current incretin-based drugs, participants experienced far fewer adverse events. Lead author Professor Timothy Garvey of the University of Alabama at Birmingham noted that petrelintide offers a viable alternative to incretin drugs, particularly for patients who cannot tolerate digestive symptoms.

Amylin Analogs Address Incretin Discontinuation Rates

Real-world data indicate that up to 75 percent of patients stop taking injectable glucagon-like peptide receptor agonist (GLP-1 RA) therapies within 12 months. Discontinuing treatment frequently results in weight regain during the first year, which can reverse improvements in cardiometabolic disease markers. Gastrointestinal symptoms remain a primary driver of treatment dropouts.

In a cardiovascular outcomes trial evaluating semaglutide, gastrointestinal side effects accounted for approximately 37 percent of treatment discontinuations. Amylin is a hormone released by the pancreas that helps regulate hunger through pathways that operate partly independent of incretins. Other amylin analogs in clinical development include cagrilintide and eloralintide, both of which seek to provide clinically meaningful weight loss with lower rates of nausea and related digestive complaints.

Phase Two Clinical Trial Design and Participant Demographics

The Phase 2 trial evaluated once-weekly subcutaneous doses of petrelintide against a placebo across 32 clinical sites in the United States, Poland, and Romania. Researchers screened 714 candidates between December 9, 2024, and February 25, 2025, ultimately randomizing 485 participants into six treatment cohorts. All cohorts received standardized lifestyle counseling that prescribed a daily energy deficit of approximately 500 kilocalories and at least 150 minutes of weekly moderate-intensity physical activity.

The trial enrolled 255 female participants (53 percent) and 230 male participants (47 percent), with a mean baseline age of 47 years. Enrolled patients presented with a mean body weight of 107.1 kilograms (236 pounds) and a mean body mass index (BMI) of 36.7 kg/m². White participants comprised 86 percent (419 individuals) of the studied cohort.

Dose Response and Measured Cardiovascular Health Changes

Petrelintide produced dose-dependent weight reduction across 42 weeks of continuous treatment. Average weight loss reached 8.7 percent in the 1.0 mg cohort, 9.2 percent at 2.5 mg, 10.7 percent at 5.0 mg, 10.5 percent at 7.0 mg, and 10.2 percent at 9.0 mg. Placebo recipients experienced an average weight reduction of 1.7 percent under the same lifestyle intervention.

Participants receiving petrelintide also achieved measurable improvements across primary cardiovascular risk indicators. The data showed reductions in resting blood pressure along with lower concentrations of C-reactive protein (CRP), an established blood marker of systemic inflammation. Petrelintide therapy also improved lipid panels by reducing blood cholesterol and triglyceride levels.

• 1.0 mg weekly petrelintide: 8.7 percent mean weight reduction
• 2.5 mg weekly petrelintide: 9.2 percent mean weight reduction
• 5.0 mg weekly petrelintide: 10.7 percent mean weight reduction
• 7.0 mg weekly petrelintide: 10.5 percent mean weight reduction
• 9.0 mg weekly petrelintide: 10.2 percent mean weight reduction
• Weekly placebo injection: 1.7 percent mean weight reduction

Current Evidence Caveats and Clinical Next Steps

Petrelintide remains an investigational drug that has not received regulatory approval from government health agencies. The Phase 2 data reflects 42 weeks of observation in a study cohort that was 86 percent white, meaning longer Phase 3 trials are required to confirm safety and efficacy across diverse populations. Weight loss plateaued near the 5.0 mg dose, showing no additional reduction at 7.0 mg or 9.0 mg.

Patients managing elevated body weight or metabolic dysregulation can talk to their clinician about whether existing therapies fit their tolerance profile while monitoring upcoming trial data for this new obesity drug targeting appetite.